Skip to main content
Premium Trial:

Request an Annual Quote

Ambion: Aug 21, 2008

Premium
Ambion, a unit of Applied Biosystems, has recently introduced a new Anti-miR microRNA inhibitor positive control for hsa-let-7c.
 
According to the company, the validated positive control can be monitored in human or mouse cells by qRT-PCR using a TaqMan gene expression assay to HGMA2.
 
Ambion has also released sets of its Silencer Select siRNAs targeting the human druggable genome in sets grouped by gene target class. The siRNAs are available in a ready-to-ship 0.25 nanomolar format or in larger customer quantities.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.